Clinical trial NCT00653458: Bioavailability Study of Ondansetron Orally Disintegrating Tablets Under Fed Conditions
Official title: Comparative, Randomized, Single-Dose, Cross Over Bioavailability Study of Kali's Ondansetron ODT 8 mg With That of GlaxoSmithKine's Zofran ODT 8 mg in Healthy Adult Subjects Under Fed Conditions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: bioequivalence
Ondansetron ODT
fed
To determine bioequivalence under fed conditions
Lead sponsor: Par Pharmaceutical, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Algorithme Pharma Inc
First posted: 2008-04-07
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER

Brief summary: To compare the single-dose bioavailability of Ondansetron ODT 8 mg and Zofran 8 mg

Detailed description: To compare the single-dose bioavailability of Kali's Ondansetron ODt 8 mg with that of GlaxoSmithKine's Zofran 8 mg under fed conditions

Eligibility criteria: Inclusion Criteria:

* Subjects meeting all of the following criteria may be included in the study
* Availability of subject for the entire study period and willingness to adhere to protocol requirements as evidenced by the informed consent from duly signed by the subject.
* Males and females aged from 18 to 50 years with a body mass index (BMI) within 19-30; demographic data (sex, age, ethnic group, body weight, height and smoking habits) will be recorded and reported in the final report.
* Clinical laboratory values within the laboratory's stated normal range; if not within this range, they must be without ant clinical significance and must be recorded as such in the CRF ( laboratory tests are presented in section 7.1.3)
* Healthy according to the laboratory results and physical examination.
* Normal cardiovascular function according to the to ECG.
* Non or ex-smokers.

Exclusion Criteria:

* Significant history of hypersensitivity to ondansetron or any related products as well as severe hypersensitivity reactions (like angioedema) to any drugs.
* Presence or history of significant gastrointestinal, liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects.
* Presence or history of significant cardiovascular, pulmonary, hematologic, neurologic, psychiatric, endocrine, immunologic or dermatologic disease.
* Females who pregnant, lactating or are likely to become pregnant during the study phases.
* Females or childbearing potential who refuse to use an acceptable contraceptive regimen throughout the study.
* Positive pregnancy test before and during the study.
* Maintenance therapy with any drug, or significant history of drug dependency, alcohol abuse (\>3 units of alcohol per day, intake of excessive alcohol, acute or chronic), or serious psychological disease.
* Any clinically significant illness in the previous 28 days before day 1 of this study.
* Use of enzyme-modifying drugs in the previous 28 days before day 1 of this study (all barbiturates, corticosteroids, phenylhydantoins, etc.)
* Participation in another clinical trial in the previous 28 days before day 1 of this study.
* Donation of 500 mL of blood (Canadian Blood Services, Hema-Quebec, clinical studies, etc.) in the previous 56 days before day 1 of this study.
* Positive urine screenings of drugs of abuse (drug names are presented in section 7.1.4).
* Positive results to HIV, HBsAg or anti-HCV tests.
* History of fainting upon blood sampling.

Primary outcomes:
measure: Rate and Extend of Absorption
timeFrame: 24 Hours
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Algotithme Pharma Inc
name: Christian Aumais
role: PRINCIPAL_INVESTIGATOR
References: